6
Oct
2026
ANFARM HELLAS S.A.
Exhibitor at CPHI Milan 2026 stand 7D49, Integrated Pharma
About Us
Categories
-
Country/Region:Greece
-
On CPHI since:2015
Primary activities
Event information
CPHI Milan 2026
-
6 Oct 2026 - 8 Oct 2026
-
Fiera Milano, Italy
-
Visit us at stand 7D49, Integrated Pharma
Products Featured at CPHI Milan 2026
-
Product Amikacin Inj.Sol 500mg/2ml (EU CTD Available) & 1g/4ml (EU CTD Available: Q3 2021)
Amikacin Solution for Injection
Reference Product: Briklin® / BRISTOL-MYERS SQUIBB
Description: Amikacin sulfate is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species,&nb... -
Product Apixaban F.C. Tabs 2.5mg/tab & 5mg/tab (under development)
Apixaban Film Coated Tablets 2.5mg & 5mg
Reference Product: Eliquis® / Bristol-Myers Squibb/Pfizer
Description: Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transie... -
Product Azithromycin Pd.Sol.Inf 500mg/Vial (EU CTD Available)
Azithromycin 500mg/Vial Powder for Solution for Infusion Reference Product: Zithromax® / PFIZER
Description: Azithromycin as powder for solution for infusion is indicated for the treatment of community-acquired pneumonia due to susceptible microorganisms in adult patients where initial intrav... -
Product Brivaracetam Oral Solution 10mg/ml (EU CTD Available: Q4 2022)
Brivaracetam 10mg/ml Oral Solution
Reference Product: Briviact® / UCB
Description: Brivaracetam is an antiepileptic agent which is indicated as adjunctive therapy in the treatment of partial onsetseizures with or without secondary generalization in adults, adolescents and children from 4 year... -
Product Brivaracetam Sol. Inf 10mg/ml (5ml Vial) (EU CTD Available: Q3 2022)
Brivaracetam 10mg/ml (5ml Vial) Solution for Injection/Infusion
Reference Product: Briviact® / UCB
Description: Brivaracetam is an antiepileptic agent which is indicated as adjunctive therapy in the treatment of partial onsetseizures with or without secondary generalization in adults, adolescents and...




